Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00292864 · ClinicalTrials.gov registry record · Phase 1
Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors
A Phase 1 study, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00292864 is a Phase 1 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT00292864, a Phase 1 study, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended phase 2 dose; and to learn more about the clinical activity of SNS-032.
Interventions
- DRUG SNS-032 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00292864
The ClinicalTrials.gov registry entry for NCT00292864 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SNS-032 Injection is the first listed.
NCT00292864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00292864 about?
NCT00292864 is a clinical study titled "Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors". The purpose of this study is to assess the safety and tolerability of one-hour infusions given once daily for 5 consecutive days in a 21-day treatment cycle; to define a recommended phase 2 dose; and to learn more about the clinical activity of SNS-032.
What is the current status of trial NCT00292864?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2006-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00292864?
The interventions under investigation include: SNS-032 Injection (DRUG).
Who is sponsoring clinical trial NCT00292864?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.